
|Videos|December 26, 2014
Dr. Gomella on Labeling Low-Risk Prostate Cancer
Author(s)Leonard G. Gomella, MD
Leonard Gomella, MD, urology specialist from Jefferson University, talks about the challenge of treating prostate cancer patients with a Gleason score of less than six.
Advertisement
Leonard Gomella, MD, chair, Department of Urology, director, Kimmel Cancer Center Network, Thomas Jefferson University Hospital, talks about the challenge of treating prostate cancer patients with a Gleason score of less than six.
Active surveillance is an appropriate treatment for the majority of those with Gleason six prostate cancer, but often the term ‘cancer’ makes patients feel like they need more aggressive treatment.
Overtreatment is a common problem, which may be solved by renaming the disease, says Gomella.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5




































